Xiuning Le, FLAURA2

Xiuning Le: Presented Dato-DXd with Osimertinib in EGFR-Refractory NSCLC Patients at ELCC25

Xiuning Le, Associate Professor at MD Anderson Cancer Center, shared a post on X:

“A very successful ELCC25 I presented Dato-DXd (4mg/kg vs 6mg/kg) with osimertinib in EGFR refractory NSCLC patients, from ORCHARD trial. mPFS 11.7 mon and ORR 36% in Dato-DXd 6mg/kg cohort.

Improving upon what we have and explore new combinations. ”

Xiuning Le: Presented Dato-DXd with Osimertinib in EGFR-Refractory NSCLC Patients at ELCC25

More posts featuring ELCC25.

cancer ELCC25 Lung cancer NSCLC OncoDaily Oncology ORCHARD trial Xiuning Le